Tania Thomas

Tania Thomas is an accomplished regulatory affairs executive with extensive experience in the pharmaceutical and biopharmaceutical industries. Currently serving as Vice President of Regulatory Affairs at Halozyme, Inc. since September 2023, Tania previously held the role of Global Vice President of Regulatory and Medical Affairs at Indivior, where a notable achievement included the acquisition of Opiant Pharmaceuticals. At Opiant Pharmaceuticals, Tania successfully led the team that achieved priority FDA approval for OPVEE (nalmefene) nasal spray, enhancing integration efforts into Indivior. Tania's background includes senior positions at GSK, managing a $4 billion OTC drugs portfolio, and at Pfizer, where leadership spanned U.S. and global regulatory activities. Early career experience includes roles at the Medicines and Healthcare products Regulatory Agency and Pharmathen, showcasing a foundation in regulatory submissions and assessments. Tania holds a Master's degree in International Management from King's College London and a Bachelor of Pharmacy from UCL.